Putri Henny Meitri Andrie Rachmasari, Novianti Putri Wikie, Pradjatmo Heru, Haryana Sofia Mubarika
Department of Obstetrics and Gynecology, Indonesia Army Hospital, Central Jakarta 10410, Indonesia.
Siena Clinical, Central Jakarta 10340, Indonesia.
Oncol Lett. 2024 Aug 12;28(4):491. doi: 10.3892/ol.2024.14624. eCollection 2024 Oct.
Ovarian cancer (OC) poses a significant health risk to women worldwide, with late diagnoses and chemotherapy resistance leading to high mortality rates. Despite several histological subtypes, the primary challenge remains the subtle nature of its symptoms, resulting in advanced-stage diagnosis and reduced treatment success rates. With platinum-based therapies showing relative efficacy but limited survival enhancements, the emergence of chemotherapy resistance during recurrence remains a critical obstacle. Precision medicine development has aimed to address these challenges in the context of the molecular diversity of OC. The present review explored the landscape of microRNA (miRNA)-mediated approaches in OC treatment. miRNAs have emerged as regulators of gene expression, serving as both oncogenes and tumor suppressors in OC. Dysregulated miRNAs are associated with disease progression and chemotherapy resistance, underscoring their significance in diagnosis and tailored treatment strategies. The present review extracted 295 publications from the PUBMED database. Out of the 73 eligible studies, 55 miRNAs were assessed. A total of three of these miRNAs were not associated with any disease or cancer, whilst eight were associated with OC, albeit also associated with other diseases. The present review encompassed three dimensions: i) The role of miRNAs in treatment efficacy; ii) the use of miRNAs to enhance therapy outcomes; and iii) adjunctive strategies for improved treatment results. Furthermore, it offered insights into potential avenues for improving OC treatment using miRNA-based approaches.
卵巢癌（OC）对全球女性的健康构成重大风险，晚期诊断和化疗耐药导致高死亡率。尽管存在几种组织学亚型，但主要挑战仍然是其症状的隐匿性，导致晚期诊断和治疗成功率降低。由于铂类疗法显示出相对疗效，但生存改善有限，复发期间化疗耐药的出现仍然是一个关键障碍。精准医学的发展旨在在OC分子多样性的背景下应对这些挑战。本综述探讨了微小RNA（miRNA）介导的方法在OC治疗中的前景。miRNA已成为基因表达的调节因子，在OC中既作为癌基因又作为肿瘤抑制因子。miRNA失调与疾病进展和化疗耐药相关，突显了它们在诊断和定制治疗策略中的重要性。本综述从PUBMED数据库中提取了295篇出版物。在73项符合条件的研究中，评估了55种miRNA。其中共有3种miRNA与任何疾病或癌症无关，而8种与OC相关，尽管也与其他疾病相关。本综述涵盖三个方面：i）miRNA在治疗疗效中的作用；ii）使用miRNA提高治疗效果；iii）改善治疗结果的辅助策略。此外，它还为使用基于miRNA的方法改善OC治疗的潜在途径提供了见解。
